Trump Orders New Federal Division to Advance Women’s Health Research

US President Donald Trump has ordered the creation of a new division within the National Institutes of Health (NIH) to strengthen research into women’s health and accelerate the translation of scientific findings into medical care.

The executive order also establishes a White House Women’s Health Task Force, co-chaired by Health Secretary Robert F. Kennedy Jr. and White House Chief of Staff Susie Wiles, to coordinate federal policy on women’s health across different stages of life.

The NIH is required to establish the new division within 90 days. It will work alongside the agency’s existing Office of Research on Women’s Health, with a mandate to improve research coordination, identify gaps in scientific understanding and help translate discoveries into better health outcomes.

The order calls for a coordinated approach to women’s health, covering needs from infancy and adolescence through pregnancy, menopause and ageing. It also directs federal agencies to consider policy and regulatory changes to support timely prevention, diagnosis, treatment and care tailored to women’s needs at different stages of life.

The administration has identified cardiovascular disease, cancer, stroke, Alzheimer’s disease, autoimmune conditions, osteoporosis, chronic pain, endometriosis, uterine fibroids, infertility, maternal health, menopause and neurological disorders among the areas requiring further research and clinical attention.

The order also revokes a 2024 executive order and a 2023 presidential memorandum on women’s health research introduced under former President Joe Biden. The Trump administration says its approach will place greater emphasis on translating research into clinical care, rather than focusing primarily on expanding research.

The announcement comes amid other health policy initiatives pursued by the administration, including changes to federal nutrition guidance, prescription drug pricing and maternal health services.

The administration says 46 states have invested in maternal health programmes, including telehealth, remote patient monitoring, obstetric workforce development and postpartum care.

In November 2025, the Food and Drug Administration began the process of removing broad “black box” warnings from hormone replacement therapy products used to treat menopause symptoms. The administration has also launched TrumpRx.gov, a platform offering discounted prescription medicines, and Moms.gov, a website providing information for new and expectant mothers.

The White House says the measures are intended to improve women’s health outcomes throughout their lives, with the new executive order placing particular emphasis on federal coordination and the application of research findings in medical practice.

Source: FSX Business News